Fear of cancer recurrence in hematopoietic cell transplantation survivors: fear of cancer recurrence in HCT survivors
One-third of long-term bone marrow transplant survivors struggle with persistent fear of cancer return—highlighting a survivorship need that deserves routine mental health support.
In 1,501 long-term HCT survivors completing standardized questionnaires, 34% met criteria for clinically significant fear of cancer recurrence, with younger survivors and those closer to transplant at highest risk. This large prospective analysis reveals an undertreated survivorship burden in hematologic malignancy patients and calls for routine integration of psychosocial screening into HCT survivorship programs.
What the study was
- Study design
- Prospective cross-sectional survey with logistic regression
- Population
- Long-term HCT survivors (>1 year post-transplant) at Fred Hutch Cancer Center
- Sample size
- 1501
- Category
- Public Health
- Maturity
- Validated
- Journal
- Transplantation and Cellular Therapy
Why it surfaced
Large well-characterized HCT survivorship cohort (n=1,501); reveals undertreated psychosocial burden with actionable implications for survivorship care design. Limited novelty relative to prior FCR literature.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.